Lenercept
Lenercept is a recombinant fusion protein that acts as a tumor necrosis factor (TNF) inhibitor. It was developed as a potential therapeutic agent for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
Mechanism of Action[edit | edit source]
Lenercept functions by binding to tumor necrosis factor alpha (TNFα), a pro-inflammatory cytokine involved in systemic inflammation. By inhibiting TNFα, Lenercept reduces inflammation and the immune response that contributes to the pathology of autoimmune diseases.
Development and Clinical Trials[edit | edit source]
Lenercept was developed in the 1990s and underwent several clinical trials to evaluate its efficacy and safety. Initial studies showed promise in reducing symptoms of rheumatoid arthritis. However, subsequent trials, particularly in multiple sclerosis, did not demonstrate significant clinical benefits and raised concerns about potential adverse effects, including increased risk of infections and other immune-related complications.
Pharmacokinetics[edit | edit source]
Lenercept is administered via subcutaneous injection. It has a half-life that allows for dosing at regular intervals, typically every two to four weeks. The pharmacokinetics of Lenercept are characterized by its ability to maintain therapeutic levels in the bloodstream, thereby providing continuous inhibition of TNFα.
Adverse Effects[edit | edit source]
Common adverse effects associated with Lenercept include injection site reactions, upper respiratory infections, and headaches. More serious adverse effects can include increased susceptibility to infections, reactivation of latent tuberculosis, and potential exacerbation of demyelinating diseases.
Current Status[edit | edit source]
Due to the mixed results in clinical trials and the emergence of more effective TNF inhibitors, Lenercept is not widely used in clinical practice today. Other TNF inhibitors, such as etanercept, infliximab, and adalimumab, have largely supplanted Lenercept in the treatment of autoimmune diseases.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
